Physician profile
Huthayfa Ateeli
NPI 1770862997
$1,051.78
in general payments reported to CMS, 2019-2025
10 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $557 · 2023: $19.92 · 2024: $40.52 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $537.88 | 2021 | |
| Glaxosmithkline, LLC. | $170.55 | 2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $117.47 | 2025 | Dupixent |
| Pulmonx Corporation | $65.31 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Genzyme Corporation | $45.06 | 2025 | |
| Inspire Medical Systems, INC. | $39.43 | 2023-2024 | Inspire |
| Verona Pharma, INC. | $21.77 | 2025 | Ohtuvayre |
| Vapotherm INC | $21.01 | 2024 | Vapotherm |
| United Therapeutics Corporation | $18.95 | 2021 | |
| Insmed, INC. | $14.35 | 2025 | Brinsupri, Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huthayfa Ateeli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.